| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/30/2006 | US20060067923 Preventing agent against drug-resistant bacterial infection |
| 03/30/2006 | US20060067914 Immortalized natural killer cell line |
| 03/30/2006 | US20060067912 Methods for the induction of professional and cytokine-producing regulatory T cells |
| 03/30/2006 | US20060067889 Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents |
| 03/30/2006 | US20060067885 ablating a targeted non-malignant B cell, comprising administering to a human subject having an immune disease an unconjugated monoclonal antibody (LL2 antibody) which binds to a marker that is specific for a B cell |
| 03/30/2006 | DE10347710B4 Rekombinante Impfstoffe und deren Verwendung Recombinant vaccines and their use |
| 03/30/2006 | CA2586793A1 Treating neoplasms with neurotoxin |
| 03/30/2006 | CA2584290A1 Staphylococcal immunogenic compositions |
| 03/30/2006 | CA2581336A1 Methods of diagnosing and treating complications of pregnancy |
| 03/30/2006 | CA2581319A1 Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection |
| 03/30/2006 | CA2580981A1 Stabilized human igg4 antibodies |
| 03/30/2006 | CA2580965A1 Monoclonal antibodies to progastrin |
| 03/30/2006 | CA2580921A1 Antibodies against and methods for producing vaccines for respiratory syncytial virus |
| 03/30/2006 | CA2580693A1 Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine |
| 03/30/2006 | CA2580208A1 Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide |
| 03/30/2006 | CA2580137A1 Immunogenic composition |
| 03/30/2006 | CA2580113A1 Purification process for bacterial cytolysin |
| 03/30/2006 | CA2580103A1 Immunogenic composition for use in vaccination against staphylococcei |
| 03/30/2006 | CA2579905A1 Cytotoxicity mediation of cells evidencing surface expression of mcsp |
| 03/30/2006 | CA2579787A1 Novel vaccine for veterinary and human medicine prophylaxis and therapy |
| 03/30/2006 | CA2577815A1 Engineered antibody fragment that irreversibly binds an antigen |
| 03/30/2006 | CA2575838A1 Anti-cd154 antibodies |
| 03/30/2006 | CA2571272A1 Anti-lympho- plus anti-monocytes globulin preparation for inhibiting immune responses |
| 03/30/2006 | CA2566840A1 Bacillus anthracis spore specific antobodies |
| 03/30/2006 | CA2563500A1 Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost |
| 03/30/2006 | CA2481716A1 Smallpox vaccination series 770 |
| 03/29/2006 | EP1640458A1 Method of selecting patients suitable for wt1 vaccine |
| 03/29/2006 | EP1640447A1 BIOACTIVE PEPTIDE-PRODUCING STRAINS OF i ENTEROCOCCUS FAECALIS /i , BIOACTIVE PEPTIDES AND APPLICATIONS THEREOF |
| 03/29/2006 | EP1640381A2 Neurotrophic growth factor |
| 03/29/2006 | EP1640018A1 Combinational therapy for treating cancer |
| 03/29/2006 | EP1640013A2 Inactivated Salmonella vaccines |
| 03/29/2006 | EP1639092A2 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 03/29/2006 | EP1639029A2 Biodegradable poly(beta-amino esters) and uses thereof |
| 03/29/2006 | EP1639012A2 Suppression of transplant rejection |
| 03/29/2006 | EP1639010A2 Surrogate therapeutic endpoint for anti-ctla-4 based immunotherapy of disease |
| 03/29/2006 | EP1638996A1 Hiv immunogenic complexes |
| 03/29/2006 | EP1638995A1 Novel surface protein (hbsag) variant of hepatitis b virus |
| 03/29/2006 | EP1638994A1 Novel surface protein (hbsag) variant of hepatitis b virus |
| 03/29/2006 | EP1638993A1 Immunomodulating compositions, uses therefor and processes for their production |
| 03/29/2006 | EP1638987A2 Nucleic acid sequences encoding and compositions comprising ige signal peptide and/or il-15 and methods for using the same |
| 03/29/2006 | EP1638919A1 Sphingolipids polyalkylamines conjugates |
| 03/29/2006 | EP1638611A1 Sphingolipids polyalkylamine conjugates for use in transfection |
| 03/29/2006 | EP1638610A1 Sphingoid polyalkylamine conjugates for vaccination |
| 03/29/2006 | EP1638606A2 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 03/29/2006 | EP1638605A2 Delivery of therapeutic compounds to the brain and other tissues |
| 03/29/2006 | EP1638603A1 Methods for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance p by using anti-substance p antibodies |
| 03/29/2006 | EP1638602A1 Vaccines against group y neisseria meningitidis and meningococcal combinations thereof |
| 03/29/2006 | EP1638601A1 Carrier proteins for vaccines |
| 03/29/2006 | EP1638600A2 Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist |
| 03/29/2006 | EP1638599A1 Vaccine composition for vaccinating dogs against canine infectious respiratory disease (cird) |
| 03/29/2006 | EP1638598A2 ACAPSULAR i P. MULTOCIDA HYAE /i DELETION MUTANTS |
| 03/29/2006 | EP1638597A2 Polyanionic polymer adjuvants for haemophilus influenza b saccharide vaccines |
| 03/29/2006 | EP1638587A2 Contraceptive methods and compositions related to proteasomal interference |
| 03/29/2006 | EP1638558A2 Pharmaceutical composition comprising a macrolide immunomodulator |
| 03/29/2006 | EP1638531A1 Antigen-containing microspheres for the treatment of allergies |
| 03/29/2006 | EP1638517A2 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
| 03/29/2006 | EP1638514A2 Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer |
| 03/29/2006 | EP1638512A2 Ligands that bind to the amyloid-beta; precursor peptide and related molecules and uses thereof |
| 03/29/2006 | EP1638510A2 Multivalent carriers of bi-specific antibodies |
| 03/29/2006 | EP1395282B1 Vaccine complex for preventing or treating leishmaniases |
| 03/29/2006 | EP1320552B1 Method for producing human anti-thymocyte immunoglobulins |
| 03/29/2006 | EP1305402B1 Lipo-viro-particle complexes, preparation method and uses |
| 03/29/2006 | EP1289552B1 Methods for treating hemostatic disorders by soluble p-selectin |
| 03/29/2006 | EP1226279B1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 03/29/2006 | EP1222266B1 Pca3 messenger rna in benign and malignant prostate tissues |
| 03/29/2006 | EP1210113B1 Combined vaccine compositions |
| 03/29/2006 | EP1100468B1 Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| 03/29/2006 | EP1086224B1 B2 microglobulin fusion proteins and high affinity variants |
| 03/29/2006 | EP1079847B1 Osteoporosis treatment |
| 03/29/2006 | EP1005363B1 Recombinant dimeric envelope vaccine against flaviviral infection |
| 03/29/2006 | EP0990031B1 Tumor necrosis factor receptor 5 |
| 03/29/2006 | EP0956343B1 Recombinant swinepox virus |
| 03/29/2006 | EP0944722B1 Pituitary-tumor-transforming-genes, and related products |
| 03/29/2006 | EP0918797B1 Humanized immunoglobulin reactive with alpha4beta7 integrin |
| 03/29/2006 | EP0914427B1 Plasmid-based vaccine for treating atherosclerosis |
| 03/29/2006 | EP0833925B1 Diagnostic test for equine arteritis virus mediated disease |
| 03/29/2006 | EP0831780B1 Improved liposomal formulation |
| 03/29/2006 | EP0751709B2 Use of bcl-2 for the manufacture of medicaments for the therapeutic treatment and prevention of diseases |
| 03/29/2006 | EP0717777B1 Salmonella vaccines |
| 03/29/2006 | CN1754002A Methods and compositions concerning poxviruses and cancer |
| 03/29/2006 | CN1753991A Monoclonal antibody, gene encoding the same, hybridoma, medicinal composition and diagnostic reagent |
| 03/29/2006 | CN1753912A Antibodies against PD-1 and uses therefor |
| 03/29/2006 | CN1753911A Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis |
| 03/29/2006 | CN1753694A Remedy for spinal injury containing interleukin-6 antagonist |
| 03/29/2006 | CN1753693A Uses of anti-insulin-like growth factor I receptor antibodies |
| 03/29/2006 | CN1753692A Lymphotoxin beta receptor agents in combination with chemotherapeutic agents |
| 03/29/2006 | CN1753691A Subcutaneously-administered ganglioside-based vaccine compositions |
| 03/29/2006 | CN1753690A Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation |
| 03/29/2006 | CN1753618A Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| 03/29/2006 | CN1752107A Preparation method of anti apoA1, apoB antibody and reagent box used for detecting apoAI, apoB |
| 03/29/2006 | CN1752106A Method of manufacturing human antibody possessing bioreceptor synergist, antagonist and/or inverse synergist |
| 03/29/2006 | CN1752104A Monoclonal antibody of synapse protein gamma and its application |
| 03/29/2006 | CN1752099A SARS-S antigen polypeptide capable of inducing producing specificity immune response |
| 03/29/2006 | CN1247788C Lentivirus-Based gene transfer vectors. |
| 03/29/2006 | CN1247775C Attenuated cattle viral diarrhoea virus |
| 03/29/2006 | CN1247614C Preparation of antigen sensitized human dendron shaped cell and its use |
| 03/29/2006 | CN1247262C Adjuvant and vaccine composition containing monophosphoryl lipid A |
| 03/29/2006 | CN1247261C Combined bacterin for treating allergic disease and preparation method |
| 03/29/2006 | CN1247258C Combination therapy using anti-angiogenic agents and TNF alpha |
| 03/28/2006 | USRE39048 substitution of the sixth amino acid Glycine of the LHRH (luteinizing hormone releasing hormone) decapeptide by D-Lysine or D-Glutamine; the resulting variant peptide is coupled to a common carrier and/or mild adjuvant; immunocastration; mammals |